Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
ipo
5
×
life sciences
national blog main
national top stories
san francisco blog main
venture capital
5
×
cancer
new york blog main
san diego blog main
san diego top stories
san francisco top stories
biogen
boston top stories
boulder/denver blog main
boulder/denver top stories
deals
detroit blog main
detroit top stories
fda
indiana blog main
indiana top stories
national
new york top stories
novartis
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
startups
texas blog main
texas top stories
vc
wisconsin blog main
wisconsin top stories
clinical trials
crispr
deerfield management
drug development
What
ipo
5
×
bio
medicines
roundup
cancer
covid
new
plans
years
acquisitions
activity
advance
allogene
announced
approvals
biogen
biology
ceo
clamped
collabs
company
crispr
cytokine
daniel
deal
delays
despite
developing
diversity
drug
drugs
economic
enhanced
family
fast
fda
files
gilead
gilead’s
hardest
Language
unset
Current search:
ipo
×
ipo
×
" venture capital "
×
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
5 years ago
Synthorx Files for IPO to Advance Enhanced Cytokine Drugs
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More